The Lancet
Actualizado 29.06.20
Abstract
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Sharpening the global focus on ethnicity and race in the time of COVID-19
Artículos anteriores
Access to health care under threat in Afghanistan
Offline: COVID-19 and the ethics of memory
Attacks against health-care personnel must stop, especially as the world fights COVID-19
Salient lessons from Russia’s COVID-19 outbreak
The starting line for COVID-19 vaccine development
A history of the medical mask and the rise of throwaway culture
Who is most likely to be infected with SARS-CoV-2?
Offline: A global health crisis? No, something far worse
Effect of the COVID-19 pandemic on cancer treatment and research
Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries
Cancer guidelines during the COVID-19 pandemic
COVID-19: protecting health-care workers
COVID-19: the medium is the message
COVID-19 and Italy: what next?
Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic
MPG Journal - Política de privacidad